SCHEMBL13006176

SCHEMBL13006176

COC(=O)/C=[N+](\[O-])Cc1cccc(-c2ccc(C(=O)N(C)C)cc2)c1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 11/20 0.40
CYP3A4 P08684 11/20 0.40
HSD17B10 Q99714 9/20 0.40
CYP2D6 P10635 7/20 0.40
TSHR P16473 4/20 0.40
CLK4 Q9HAZ1 4/20 0.40
ALOX15 P16050 4/20 0.40
CYP2C19 P33261 7/20 0.37
USP2 O75604 4/20 0.37
LMNA P02545 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALDH1A1 P00352 5/20 0.35
MAPK1 P28482 2/20 0.35
ERN1 O75460 2/20 0.34
MAPT P10636 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
FYN P06241 1/20 0.34
LPAR1 Q92633 1/20 0.34
KDM4E B2RXH2 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13006167 0.87 NPC1 (0.39) CYP1A2CYP3A4HSD17B10CYP2D6TSHR
SCHEMBL13006175 0.78 CYP1A2 (0.47) CYP1A2CYP3A4HSD17B10CYP2D6TSHR
SCHEMBL10266279 0.75 KMT2A (0.34) LMNAALDH1A1MAPK1MAPTMEN1
SCHEMBL13006174 0.71 ERN1 (0.53) CYP1A2CYP3A4HSD17B10CYP2D6TSHR
SCHEMBL13061005 0.68 KCNA5 (0.49) CYP3A4TSHRLMNAERN1HPGD
SCHEMBL12718963 0.68 MAPT (0.36) LMNAALDH1A1MAPK1MAPTMEN1
SCHEMBL13005779 0.67 CYP1A2 (0.38) CYP1A2CYP2D6CYP2C19LMNACYP2C9
SCHEMBL13060854 0.66 NPC1 (0.46) CYP1A2CYP3A4HSD17B10CYP2D6TSHR
SCHEMBL15655702 0.66 MEN1 (0.49) CYP1A2CYP3A4HSD17B10CYP2D6TSHR
SCHEMBL10265250 0.66 MEN1 (0.36) TSHRALDH1A1MAPK1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed